Breast Cancer
Danaher’s Leica division to buy Devicor Medical Products
Breast cancer: GE Healthcare wins pivotal FDA approval for 3D breast imaging
Imaging giant GE Healthcare (NYSE:GE) won FDA approval for its 3D breast tomosynthesis imaging system, MassDevice.com has learned.
Press Release: Siemens files PMA for digital breast tomosynthesis
MALVERN, Pa. — Siemens Healthcare has announced that it recently submitted to the U.S. Food and Drug Administration (FDA) its premarket approval application (PMA) for the MAMMOMAT Inspiration® with Breast Tomosynthesis option.
Siemens seeks FDA approval for next-gen mammograms with tomosynthesis
Dune Medical secures $14M for breast cancer detection
Israeli imaging systems maker Dune Medical Devices touted the successful raise of $14 million in equity financing, looking to secure another $7 million before October to support its commercialization efforts.
Press Release: VuCOMP Announces FDA Approval of M-Vu Computer-Aided Detection (CAD) for Mammography Version 3.1
VuCOMP lands FDA nod for updated M-Vu mammography system
Cancer detections systems maker VuCOMP announced this week that it won FDA approval for new computer-aided detection software, launching version 3.1 of its M-Vu CAD for mammography.
Press Release: GE Healthcare Announces FDA Approval of Invenia Automated Breast Ultrasound System
GE Healthcare wins FDA approval for dense-breast mammograms
GE Healthcare (NYSE:GE) announced this week that it won FDA approval for its Invenia Automated Breast Ultrasound system, indicated to help doctors identify cancers in women with dense breast tissue.
Study: Most women getting double mastectomies don’t need them | MassDevice.com On Call
MASSDEVICE ON CALL — The majority of women who’ve had both breasts removed following a breast cancer diagnosis probably didn’t need to take such drastic measures, according to a new study.
Researchers from the University of Michigan Comprehensive Cancer Center reported that as much as 70% of women who opted for a double mastectomy following breast cancer did so despite a very low risk of recurrence.